image

Metformin Use Improves Cardiometabolic Health and Enhances Survival in Cancer Survivors

29 Jun 2024 • Metformin use was found to significantly lower the risk of cardiometabolic diseases, all-cause mortality, and cardiometabolic mortality in a cohort study of US cancer survivors.

  • The study used a nationally representative sample of cancer survivors from the US National Health and Nutrition Examination Survey (NHANES) spanning from 2003 to 2018. Patient interviews, physical examinations, and mortality archives were used to collect data.

  • In this study involving 3995 cancer survivors metformin usage (448 individuals) was associated with lower risks of all-cause mortality (HR 0.62) and cardiometabolic mortality (HR 0.65) compared to non-users. Metformin users also had lower risks of total cardiovascular disease, stroke, hypertension, and coronary heart disease. These benefits were consistent across subgroups of cancer survivors identified as high risk for cardiometabolic conditions.

Source:BMC Medicine| Read full story

Contact us

support@medflix.app

+91 9023-729662

Medflix Logo

© 2025 Plexus Professionals Network Pvt Ltd

InstagramFacebookTwitter